Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | PRKCA | P17252 | 4/20 | 0.68 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.68 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.68 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.68 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.63 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821333 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25449045 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL29306783 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL26021857 | 1.00 | ALDH1A1 (0.79) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25818841 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL15369111 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL26208578 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25818802 | 0.97 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL1080161 | 0.95 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18159452 | 0.92 | ALDH1A1 (0.75) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286903-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-11744801-B2 | Methods of making lipid nanoparticles | MODERNATX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230235321-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | ORTHOBIO THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286903-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | ALDH1A1 4727/4885LMNA 712/4885PRKCA 4108/4885 |
| US-20230235321-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | SYVN1, COL2A1, UTRN | ALDH1A1 1559/4885LMNA 2651/4885PRKCA 518/4885 |
| US-11744801-B2 | Methods of making lipid nanoparticles | PLTP, LNPEP, LNPK | ALDH1A1 3846/4885LMNA 262/4885PRKCA 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.